NCT02324582View on ClinicalTrials.gov

MK-3475/BCG in High Risk Superficial Bladder Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 18, 2021

Study Completion Date

March 27, 2023

Conditions
Bladder Cancer
Interventions
DRUG

Intravenous MK-3475/ Intravesical BCG

6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.

Trial Locations (3)

48202

Henry Ford Health Systems, Detroit

62702

Simmons Cancer Institute-SIU School of Medicine, Springfield

Southern Illinois University School of Medicine, Springfield

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Southern Illinois University

OTHER

NCT02324582 - MK-3475/BCG in High Risk Superficial Bladder Cancer | Biotech Hunter | Biotech Hunter